Novel treatment strategies for aggressive non-Hodgkin's lymphoma

被引：5

作者：

Fayad, L ^{[1
]}

Younes, A ^{[1
]}

机构：

[1] Univ Texas, MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Houston, TX 77030 USA

来源：

EXPERT OPINION ON PHARMACOTHERAPY | 2006年 / 7卷 / 06期

关键词：

Akt; aurora; BAFF; CD40; Hsp-90; HDAC; mTOR; PLK; TRAIL;

D O I：

10.1517/14656566.7.6.733

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The World Health Organization has included different types of lymphoma under the aggressive category. In the US, diffuse large B-cell lymphoma is the most common aggressive lymphoma and accounts for > 30% of the 55,000 new cases diagnosed annually. Recent advances in the knowledge of the molecular biology have provided an increased understanding of the heterogeneity of non-Hodgkin's lymphoma. New treatments, especially those with the use of monoclonal antibodies, are improving both the survival and the response rate.

引用

页码：733 / 748

页数：16

共 50 条

[31] Translation initiation complex eIF4F is a therapeutic target for dual mTOR kinase inhibitors in non-Hodgkin lymphoma [J].

Demosthenous, Christos ;

Han, Jing Jing ;

Stenson, Mary J. ;

Maurer, Matthew J. ;

Wellik, Linda E. ;

Link, Brian ;

Hege, Kristen ;

Dogan, Ahmet ;

Sotomayor, Eduardo ;

Witzig, Thomas ;

Gupta, Mamta .

ONCOTARGET, 2015, 6 (11) :9488-9501

[32] Clinicopathologic and molecular features of Hodgkin's lymphoma [J].

Younes, A ;

Carbone, A .

CANCER BIOLOGY & THERAPY, 2003, 2 (05) :500-507

[33] Silencing of CKIP-1 promotes tumor proliferation and cell adhesion-mediated drug resistance via regulating AKT activity in non-Hodgkin's lymphoma [J].

Zhu, Xinhua ;

Ouyang, Yu ;

Zhong, Fei ;

Wang, Qiru ;

Ding, Linlin ;

Zhang, Peipei ;

Chen, Lingling ;

Liu, Hong ;

He, Song .

ONCOLOGY REPORTS, 2017, 37 (01) :622-630

[34] Lymphoma cell adhesion-induced expression of B cell-activating factor of the TNF family in bone marrow stromal cells protects non-Hodgkin's B lymphoma cells from apoptosis [J].

Lwin, T. ;

Crespo, L. A. ;

Wu, A. ;

Dessureault, S. ;

Shu, H. B. ;

Moscinski, L. C. ;

Sotomayor, E. ;

Dalton, W. S. ;

Tao, J. .

LEUKEMIA, 2009, 23 (01) :170-177

[35] Lymphoma cell adhesion-induced expression of B cell-activating factor of the TNF family in bone marrow stromal cells protects non-Hodgkin's B lymphoma cells from apoptosis [J].

T Lwin ;

L A Crespo ;

A Wu ;

S Dessureault ;

H B Shu ;

L C Moscinski ;

E Sotomayor ;

W S Dalton ;

J Tao .

Leukemia, 2009, 23 :170-177

[36] A Preliminary Association Study of H19 Non-Coding Gene Variants With Risk of Non-Hodgkin Lymphoma: A Case-Control Study and Computational Analysis [J].

Kashani, Sara ;

Sasan, Hoseinali ;

Mollashahi, Behrouz ;

Bahari, Gholamreza ;

Hashemi, Seyed Mahdi ;

Taheri, Mohsen .

JOURNAL OF CLINICAL LABORATORY ANALYSIS, 2025, 39 (11)

[37] Human Umbilical Cord Mesenchymal Stem Cells as Vehicles of CD20-Specific TRAIL Fusion Protein Delivery: A Double-Target Therapy against Non-Hodgkin's Lymphoma [J].

Yan, Cihui ;

Li, Shuangjing ;

Li, Zhenzhen ;

Peng, Hongwei ;

Yuan, Xiangfei ;

Jiang, Linlin ;

Zhang, Yanjun ;

Fan, Dongmei ;

Hu, Xiao ;

Yang, Ming ;

Xiong, Dongsheng .

MOLECULAR PHARMACEUTICS, 2013, 10 (01) :142-151

[38] Circulating Tfh1 (cTfh1) cell numbers and PD1 expression are elevated in low-grade B-cell non-Hodgkin's lymphoma and cTfh gene expression is perturbed in marginal zone lymphoma [J].

Byford, Elliot T. ;

Carr, Matthew ;

Ladikou, Eleni ;

Ahearne, Matthew J. ;

Wagner, Simon D. .

PLOS ONE, 2018, 13 (01)

[39] MEPED as salvage therapy for relapsed/refractory Hodgkin's lymphoma incorporating edited non-oncogene addiction: mTOR as a bottleneck [J].

Harrer, Dennis Christoph ;

Lueke, Florian ;

Pukrop, Tobias ;

Ghibelli, Lina ;

Reichle, Albrecht ;

Heudobler, Daniel .

FRONTIERS IN PHARMACOLOGY, 2025, 16

[40] Developments in Burkitt's lymphoma: novel cooperations in oncogenic MYC signaling [J].

Spender, Lindsay C. ;

Inman, Gareth J. .

CANCER MANAGEMENT AND RESEARCH, 2014, 6 :27-38

← 1 2 3 4 5 →